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A B S T R A C T
Purpose: To analyze the adverse events (AEs) signiﬁcantly associated with levetiracetam (LEV) therapy
through a meta-analysis of all available double-blind, randomized placebo-controlled trials (RCTs),
performed in any age, gender, ethnic background and disease. General tolerability and study
withdrawals due to AEs associated with LEV treatment were also investigated. In addition, a dose–
effect responses relationship for all variables was assessed.
Methods: RCTs were identiﬁed searching Medline (PubMed), Embase and Cochrane CENTRAL for the
words ‘‘Levetiracetam’’ and ‘‘randomized controlled trial’’, with different search strategies, setting the
limits ‘‘humans’’ and ‘‘English’’. Very common and common AEs according to the summary of product
characteristics were investigated.
RevMan version 5.2 was used for the statistical analyses. Risk difference with 95% conﬁdence
intervals was used to investigate the association of any AEs and withdrawal with LEV.
Results: Twenty-six studies with 2832 patients were included in the RCTs analysis. Nasopharyngitis,
somnolence, dizziness, nervousness/irritability and asthenia/fatigue were statistically signiﬁcant
associated with LEV. In addition, LEV was signiﬁcantly associated with an increased risk of AEs-related
withdrawals. No dose–response relationship was found for any of the assessed variables.
Conclusions: This ﬁrst large meta-analysis suggests that participants were more likely to discontinue LEV
than placebo.
The AE proﬁle conﬁrmed that LEV is associated with few unfavorable sedative, vestibulocerebellar
and behavioral effects, such as nervousness and irritability. However, there does not seem to be a clear
dose–response relationship.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Levetiracetam (LEV) is an antiepileptic drug with multiple
mechanisms of action that correlates with his broad spectrum of
activity. It inhibits neuronal hyper-synchronization, most likely
by binding to synaptic vesicle protein 2a (SV2A) located in
presynaptic membranes [9,23,43]: this is a mechanism of action
related to its antiepileptic activity and which might be interesting
in relation to treatment of neuropathic pain [11,18] and dyskinesia* Corresponding author at: Department of Pediatrics, University of Perugia,
Piazza Universita` 1, 06123 Perugia, Italy. Tel.: +39 075 5784417.
E-mail address: averrott@unich.it (A. Verrotti).
http://dx.doi.org/10.1016/j.seizure.2015.07.004
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights rein Parkinson disease, tardive dyskinesia, tic disorders and
Huntington’s disease [9]. LEV also activates the g-aminobutyric
acid (GABA) and glycine system, interacts with the AMPA
receptors, and partially depresses the N calcium current: all
targets that have been associated with alcohol-seeking and
drinking behavior [12].
The wide broad spectrum of activity of LEV is supported by
various double-blind studies that demonstrated its effectiveness
and safety as add-on therapy in generalized epilepsies, such as
myoclonic seizures [25], or primary generalized tonic–clonic
seizures [4], and in partial-onset seizures [15,31]. The FDA
approved LEV as an adjunctive therapy for partial onset seizures
in adults and children 4 years of age, adjunctive therapy in the
treatment of myoclonic seizures in adults and adolescents 12served.
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therapy in the treatment of primary generalized tonic–clonic
seizures in adults and children 6 years of age with idiopathic
generalized epilepsy. In contrast, the EMEA approved LEV for the
treatment of partial-onset seizures with or without generalization
in patients from one month of age, juvenile myoclonic epilepsy in
patients from 12 years of age, and of idiopathic generalized
epilepsy in patients from 12 years of age.
LEV has a favorable pharmacokinetic proﬁle that has been
determined over a dose range of 500–5000 mg for adults and 20–
30 mg/kg for children [11,12]. Different randomized controlled
trials (RCTs) and some meta-analyses [22,24,26] have shown a
good safety proﬁle for this drug. However, up to now, there are no
large meta-analyses performed on all available RCTs on LEV in any
condition. In fact, the existing meta-analyses separately evaluated
the RCTs performed only on a speciﬁc disorder.
The aim of our study was to carry out a comprehensive meta-
analysis on the safety proﬁle of LEV using a large sample of RCTs
in adults and children with regard to dose-dependent effects.
2. Methods
2.1. Criteria for considering studies in this review
2.1.1. Types of studies
We included only double-blind, placebo-controlled RCTs with
parallel or crossover design that investigated the therapeutic effect
of oral LEV in children and adults with various diseases. Studies
performed on healthy volunteers and/or lasting less than 4 weeks
were excluded. Full journal publications or summary clinical trial
reports were required. Brief abstracts were excluded. Other types
of studies, including non-randomized trials, case reports, or clinical
observations, were not included.
2.1.2. Types of participants
Subjects with any age and ethnic background taking LEV for any
clinical disorder, including partial or generalized epilepsy, essen-
tial tremor, multiple sclerosis, alcohol dependence, neuropathic
pain, polyneuropathy, bipolar depression, social anxiety disorder,
dyskinesia in Parkinson’s disease. Studies on participants who
underwent a concomitant drug therapy were included.
2.1.3. Search methods for identiﬁcation of studies
In April 2013, we conducted a computer search of Medline
(PubMed version), EMBASE and Cochrane library for all double-
blind placebo-controlled studies performed on LEV. Therefore, the
limit ‘‘humans’’ was set and we restricted our search to articles
written in English. Search strategies and a ﬂow diagram of the
selection process are available in Appendix A (Fig. A1).
Reference lists of retrieved articles were examined and
summary clinical trial reports not available as full publication
were searched on the Internet in order to ﬁnd additional articles.
Both studies randomizing patients to a ﬁxed or a ﬂexible dose of
LEV were selected for the purpose of this meta-analysis.
Eligibility was determined after reading each study identiﬁed
by our research; two blinded reviewers independently assessed
trials for inclusion in the meta-analysis. Any disagreements were
resolved by discussion. Further details are provided in Appendix B.
2.2. Analysis of adverse events
2.2.1. Selection of adverse events
Relevant adverse events (AEs) were selected following a three-
step strategy: (1) identiﬁcation of synonyms (Appendix B,
Table B1), which were grouped under one main term; (2) exclusion
of rare AEs and very rare AEs (respectively from 1/10,000 to 1/1000and less than 1/10,000, as reported by information leaﬂet) among
those randomized to LEV or placebo (PCB); (3) exclusion of not
assessable AEs, such as those reported in a single study and those
not ascribable to a clear number of patients. After selecting those
AEs to be included in our analyses, we extracted the frequency of
each AE reported from LEV and PCB groups of each study. This
information was recorded into a separate data extraction sheet.
2.2.2. Statistical analysis
Statistical analyses were performed using RevMan version
5.2 and IBM SPSS Statistics 19.0 [19,57]. Statistical heterogeneity
between trials was checked for each outcome using a Chi2 test for
heterogeneity. The I2 test was also used to assess statistical
heterogeneity, with an I2 > 70% indicating heterogeneity. Where
signiﬁcant heterogeneity was present (only for asthenia/fatigue
and dizziness at 2000 mg/day), random-effect method was used.
A ﬁxed-effect model was used in all other outcomes showing no
signiﬁcant heterogeneity. The preferred estimator was the Mantel–
Haenszel risk difference (RD). For the outcomes, 95% conﬁdence
intervals (CIs) were set.
We evaluated: (1) RDs to assess the association of general
tolerability (any AE), included in this analysis with LEV treatment;
(2) RDs to assess the association of patients withdrawing from
studies, because of AEs due to LEV; (3) RDs of 12 AEs, those
described in an adequate number (>3) of included studies, in order
to ﬁnd which AEs were signiﬁcantly associated to LEV therapy; (4)
RDs to investigate dose–response relationships of LEV in term of
general tolerability, withdrawal and AEs. For this latter purpose,
only those studies (n = 21) in which subjects were randomized to
ﬁxed-dose regimens (1000, 2000, 3000 mg/day) were selected,
since in studies allowing ﬂexible-dose regimens (n = 4) it was not
possible to assign an AE to a speciﬁc drug dose. Therefore, all
children taking a ﬂexible dose were excluded from this analysis,
while adolescents (>13 y) receiving the same dosage than adults
were not excluded. Given that only one included study Betts et al.
[5] adopted a drug regimen of 4000 mg/day, that could not be
included in the dose–response analysis.
In order to easy interpret the dose–response relationships, each
RD estimate was complemented by the computation of the number
needed to harm (NNH). An inverse variance-weighted meta-
regression model was also applied to test the relationship between
LEV dose and RDs.
3. Results
3.1. Included studies
Twenty-ﬁve studies (2832 participants) satisﬁed our inclusion
criteria and were entered into our analysis (Table 1). Twelve
studies were performed with a total of 2114 epileptic patients,
mainly affected by refractory partial seizures (1831, 86.6%), 283
(13.4%) with idiopathic generalized epilepsy. The remaining
13 studies were performed in 468 (22.1%) patients affected by
other diseases (for more information see Appendix C). In all
studies, AEs were calculated on the intention-to-treat (ITT)
population. The total number of patients treated with the active
drug was1698, whereas patients treated with PCB were 1329.
In two trials the participants were only children (N = 296) with
an age range of 4–16 years. Thirteen studies analyzed only adults
patients (N = 718, age range from 21 to 83 years). In the remaining
10 trials the study population includedboth adults and children
(age range from 4 to 70 years).
The majority of trials had parallel study design, while only 7 had
a crossover design.
Most trials recruited patients from USA and Europe, 2 trials
recruited participants from China, 1 from Taiwan and the other
Table 1
Characteristics of included studies divided into studies on epileptic patients (A) and non-epileptic patients (B).
Author Disease Population
studied
Titration
phase
(weeks)
Study
duration
(weeks)
N of
patients
(LEV/PCB)
Drug dose
1000
mg/die
2000
mg/die
3000
mg/die
4000
mg/die
Flexible
dose (n)
Berkovic 2007 [4] Idiopathic generalized
epilepsy
A + C
4–65 y
4 24 79/84 a3000 mg/day
for adults
a60 mg/kg/day
for children
Noacthar 2008 [25] Idiopathic generalized
epilepsy
with myoclonic
seizures
A + C
13–52 y
4 16 60/60 60
Ben-Menachem
2000 [3]
Refractory partial seizures A + C
16–70 y
4 16 181/105 181
Betts 2000 [5] Refractory epilepsy A + C
16–67 y
/ 24 80/39 42 38
Cereghino 2000 [8] Refractory partial seizures A + C
16–70 y
4 18 199/95 98 101
Glauser 2006 [15] Partial seizures C
4–17 y
4 14 101/97 a60 mg/kg/day
Levisohn 2009 [21] Partial onset seizures C
4–16 y
4 12 64/34 a60 mg/kg/day
Peltola 2009 [28] Partial-onset seizures A + C
12–70 y
/ 12 77/79 77
Shorvon 2000 [35] Refractory partial-onset
seizures
A + C
14–69 y
4 16 212/112 106 106
Tsai 2006 [39] Refractory partial-onset
seizures
A + C
16–60 y
2 14 47/47 47
Wu 2009 [46] Refractory partial-onset
seizures
A + C
16–70 y
4 16 103/103 103
Xiao 2009 [47] Refractory partial-onset
seizures
A + C
16–70 y
4 16 28/28 28
Elble 2007 [10] Essential tremor A
35–83 y
5 24 15/15 CO 7 + 8
Handforth 2004
[17]
Essential tremor A
67–81 y
4 16 12/10 CO 7 + 5
Falah 2012 [11] Multiple sclerosis A
31–63 y
15 d 13 30/27 CO 15 + 15
Fertig 2012 [12] Alcohol dependence A
36–58 y
4 16 64/65 64
Finnerup 2009 [13] Spinal cord injury pain A
41–63 y
2 11 34/32 CO 18 + 16
Holbech 2011 [18] Painful polyneuropathy A
21–74 y
15 d 13 37/37 CO 21 + 16
Jungehulsing
2013 [34]
Central neuropathic
post-stroke pain
A
40–76 y
4 20 40/36 CO 21 + 19
Saricicek 2011 [33] Bipolar depression A
35–67 y
b 6 19/16 19
Stein 2010 [38] Social anxiety disorder A
24–47 y
6 12 111/106 111
Vilholm 2008 [42] Post-mastectomy pain
syndrome
A
38–80 y
Not stated 9 25/25 25
Stathis 2011 [37] Levodopa-induced
dyskinesia in Parkinson’s
disease
A
59–75
1 19 38/38 CO 38
Wolz 2010 [43] Levodopa-induced
dyskinesia in Parkinson’s
disease
A
55–72 y
7 15 17/14 17
Woods 2007 [45] Tardive dyskinesia A
35–58 y
c 12 25/25 25
a Up to; A: adults; C: children; CO: cross-over study; OC: oral contraceptive.
b Titrated upwards every 1 week from 250 mg twice daily to the target dosage between 500 and 3000 mg/day.
c Escalated weekly by 500 mg/day to the maximum dose of 3000 mg/day.
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Mexico, Australia, New Zealand, USA, Canada, South Africa, India
and Russia).
The treatment period included an up-titration followed by a
maintenance phase in all but 2 trials, which did not include a dose-
up titration period. Treatment duration ranged from 2 to 24 weeks
(up-titration range 4 days to 7 weeks).LEV dosage ranged from 30 mg/kg/day to 60 mg/kg/day for
children and from 500 mg/day to 4000 mg/day for adults. The trial
performed by Betts et al. [5] was the only one in which a 4000 mg
dose was tested.
The RCTs included in our analysis investigated the use of LEV in
very different disorders, including partial (10) and generalized
epilepsies (2), essential tremor (2), multiple sclerosis (1), alcohol
A. 
B.
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Fig. 2. Number needed to harm (NNH) at LEV 1000, 2000, and 3000 mg/day for all*
statistically signiﬁcant AEs (A), risk of withdrawals and Any AE (B). (*)
nasopharyngitis has been excluded because this AE did not show statistical
signiﬁcance when grouped by dosage.
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central neuropathic post-stroke pain (1), bipolar disorder (1),
L-Dopa or tardive dyskinesia (1), social anxiety disorder (1) and
post-mastectomy syndrome (1).
Many concomitant drugs were administered to patients during
the trials (see Appendix C).
Data for AEs were available in all studies, while data for
withdrawals were lacking in 3 trials.
The minimal incidence required for each AE was set between
5 and 10%, but not all authors set a minimal percentage.
3.2. General tolerability
General tolerability was assessed by evaluating the number of
patients reporting at least one AE. The overall RD for ‘any AE’ did
not reach statistical signiﬁcance (RD 0.02, 95% CI 0.02 to 0.05).
When compared by dosage, a staistical signiﬁcance was found only
for the 3000 mg dosage (RD 0.07; 95% CI 0.01–0.12) compared to
1000 mg and 2000 mg (RD 0.01; 95% CI 0.08 to 0.06 and RD
0.18; 95% CI 0.21 to 0.56 respectively), as shown also by NNH
values (Figs. 2b and 3b, Appendix B, Table B2).
3.3. Treatment withdrawals
The overall RD discontinuation for AEs at any age was 0.03 (95%
CI 0.01–0.05); thus there was signiﬁcant evidence that participants
were more likely to discontinue LEV than PCB. Dose-withdrawal
analysis showed a lower RD in patients taking 1000 mg (0.01, 95%
CI 0.04 to 0.03) compared to patients taking 2000 mg and
3000 mg (respectively 0.05, 95% CI 0.01 to 0.09 and 0.04, 95% CI
0.01 to 0.06). (Figs. 1, 2b and 3b). In Fig. 2b data are reported as
NNH. In the regression analysis, the risk of withdrawal due to AEs
was not dose-dependent (p = 0.186).
3.4. Adverse effects
From our analysis, the AEs associated with LEV were: nasophar-
yngitis (RD 0.03; 95% CIs 0.00–0.06), nervousness/irritabilityFig. 1. Forest plot of RDs (95% CI) for all assessed AEs.(RD 0.06; 95% CIs 0.02–0.09); somnolence (RD 0.07; 95% CIs
0.05–0.09); asthenia/fatigue (RD 0.07; 95% CIs 0.04–0.10) and
dizziness (RD 0.04; 95% CIs 0.02–0.06) (Figs. 1, 2a and 3a).
3.5. Dose–effect correlations of statistically signiﬁcant levetiracetam
adverse effects
We excluded 4 studies because they use ﬂexible-dose regimens
or they provided unclear data. Therefore, the sample eligible for
this analysis was represented by 21 studies, including adults and
adolescents (>13 years). RDs (95% CIs) for the statistically
signiﬁcant LEV AEs at different doses are shown in Table 2 (see
Table B2 in appendix for more information). When grouped by
dosage, statistical signiﬁcance was reached only by somnolence,
nervousness/irritability, and dizziness at 1000 mg/day, somno-
lence at 2000 mg/day, whereas all four AEs were statistically
signiﬁcant at LEV 3000 mg/day. A statistically signiﬁcant dose–
response relationship was not found, as conﬁrmed by the
regression analyses (p = 0.134; p = 0.819; p = 0.135; p = 0.688
respectively for asthenia/fatigue, somnolence, dizziness and
nervousness/irritability) and NNH values (Fig. 2a). Nasopharyngi-
tis did not reach statistical signiﬁcance when grouped by dosage.
4. Discussion
Accurate analysis of AEs is essential for the optimal choice of
AED, given that AEs may lead to treatment discontinuation in up to
25% of patients, and contribute to poor patient adherence [29,30].
Several studies have shown that AEDs may remarkablydiffer for
Fig. 3. (A) RDs (95% CIs) for all the assessed variables in patients randomized to LEV at 1000 mg/day, 2000 mg/day and 3000 mg/day. (B) Focus on RDs of withdrawals in
patient randomized to LEV at 1000 mg/day, 2000 mg/day and 3000 mg/day.
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almost impossible to assess [52].
Previous analyses aimed at assessing efﬁcacy and tolerability
of AEDs [32,48,52,53], but they failed to show a signiﬁcant
association between the drug and several AEs, as these studies
were restricted to RCTs. Therefore, the number of recruited
patients was hampered by insufﬁcient large sample sizes to fully
uncover the AE proﬁle of a given AED.
Recent evidence, however, suggests that non-epilepsy studies
can be merged with epilepsy studies in meta-analyses of RCTs
of AEDs [36,50,54,55]. Thus, by taking into account the little drug
interaction of LEV [27] we decided to extend the target group
also to non-epileptic patients. Moreover, a combined analysis of
children and adults was performed in order to extend our sample.
In this meta-analysis of all available RCTs of LEV, we included
2832 patients and found 5 AEs signiﬁcantly associated with LEV
treatment, while Mbizvo et al. [24] meta-analysis, performed on
11 trials for a total of 1861 patients identiﬁed 2 AEs signiﬁcantly
associated with LEV: somnolence (RR 1.58; 99% CIs 1.14–2.18) andTable 2
Risk difference [95% CIs] for 5 statistically signiﬁcant AEs, withdrawals and any AE
at different doses.
AEs 1000 mg 2000 mg 3000 mg
Somnolence 0.06 [0.02, 0.11] 0.09 [0.03, 0.15] 0.08 [0.04, 0.11]
Nervousness/
irritability
0.06 [0.06, 0.06]a 0.05 [0.05, 0.05]a 0.07 [0.00, 0.13]
Dizziness 0.05 [0.01, 0.09] 0.03 [-0.02, 0.07] 0.06 [0.02, 0.10]
Asthenia/fatigue 0.02 [0.03, 0.07] 0.10 [0.06, 0.26] 0.07 [0.03, 0.11]
Nasopharyngitis 0.01 [0.01, 0.02] 0.01 [0.02, 0.05] 0.01 [0.01, 0.02]
Withdrawals 0.01 [0.04, 0.03] 0.05 [0.01, 0.09] 0.04 [0.01, 0.06]
Any AE 0.01 [0.08, 0.06] 0.18 [0.21, 0.56] 0.07 [0.01, 0.12]
a Only one study.infection (RR 1.76; 99% CIs 1.03–3.02). Furthermore, in the Mbzivo
study there was insufﬁcient evidence that participants were more
likely to discontinue LEV than PCB (RR 1.03; 95% CIs 0.80–1.33). Lo
et al. [22] performed another meta-analysis of 10 RCTs: the
likelihood of serious AEs requiring withdrawal from the study was
not signiﬁcantly different between LEV patients and controls
(RR = 1.37; 95% CIs 0.88–2.13). The meta-analysis of Zaccara et al.
[51] was performed on 5 RCTs and found only somnolence being
associated with LEV (RD 0.07; 95% CIs 0.01–0.12).
In previous meta-analyses speciﬁcally focused on the assess-
ment of tolerability of AEDs from all RCTs, 20 AEs were signiﬁcantly
associated with pregabalin (PGB) in a population of almost
12.000 subjects [50], 11 AEs were signiﬁcantly associated with
lacosamide (LCM) between more than 3000 patients [55], and
5 AEs were associated with perampanel (PER) in a population of
almost 4000 patients [53], while no AEs were associated with
zonisamide in a similar study performed in a more restricted
population of 1184 patients [41]. Compared to Levite spectrum of
the AEs observed with the other AEDs is wider for PER and PGB
and narrower for LCM. Vestibulocerebellar dysfunction resulted
a common effect of all these AEDs [6].
In the current study, the 5 AEs signiﬁcantly associated with LEV
were: nasopharyngitis, somnolence, asthenia/fatigue, dizziness
and nervousness/irritability. The association between nasophar-
yngitis and LEV has already been described by Mbizvo et al.
[24]. Although we restricted the synonyms to upper respiratory
tract infections, a possible explanation for the high frequency of
nasopharyngitis may be an overlap in reporting caused by the
variety of terms. Other authors suggested that the improvement in
seizure control may favor socialization and consequently increase
the risk of respiratory infections [7,51]. However, the correlation
between nasopharyngitis and LEV remains unclear, given that
previous analyses did not show a concomitant decrease in white
A. Verrotti et al. / Seizure 31 (2015) 49–5554blood cell and neutrophil count suggesting a reduction of
immunologic response to LEV [14].
Both somnolence and asthenia/fatigue may reﬂect the depres-
sant CNS effect of LEV. Asthenia and fatigue might also result from
decreased excitatory activity [56]. Somnolence and even more
serious disturbances of vigilance and alertness are commonly
impaired in individuals taking traditional AEDs [2]. Somnolence
and some cognitive disturbances (confusional state, abnormal
thinking, disturbance of attention) were signiﬁcantly associated
with PGB [50], while somnolence was associated with PER [53] and
was uncommon with LCM [55].
A further AE associated with LEV was nervousness/irritability,
which has already been reported in a previous systematic review of
open label studies aimed at assessing behavioral effects of LEV in
children [16]. Psychiatric effects, such as anxiety, depression and
psychosis, were very rarely associated with LEV in RCTs. Only long-
term observational studies provided data about an increased risk
of psychiatric disorders in a subset of patients with pre-existing
mood disorders [20], likely due to a genetic predisposition
[44]. These AEs are infrequent with several AEDs but signiﬁcantly
associated with PER [54]. Dizziness, which is a subjective AE, was
the only AE related to vestibulocerebellar/brainstem dysfunction
associated with LEV. Other objective and more severe AEs caused by
involvement of the same brain structures (ataxia, diplopia, balance
disorders, and so on) are commonly observed in individuals treated
with AEDs acting on voltage-gated sodium channels, such as
phenytoin, carbamazepine, lamotrigine, and oxcarbazepine [49] and
have also been found signiﬁcantly associated with PGB and LEV [48].
Probably, the different spectrum of AEs linked to LEV is caused
by its peculiar mechanism of action: the predominant effect of LEV
on cortical function and alertness may be attributed to its action on
the GABA and SV2A receptors. Moreover, the anti-epileptic actions
of LEV seem to be mediated, at least partly, via the combination of
inhibitory effects on depolarization-induced and Ca2+-induced
Ca2+ release-associated neurotransmitter releases.
An interesting ﬁnding of our meta-analysis was the unclear
relationship between LEV tolerability and dose.
Speciﬁcally, LEV tolerability, measured as percentage of
patients withdrawing because of AEs and as percentage of patients
with any AE, showed a particular dose-relationship (see Figs. 2b
and 3). Whereas tolerability clearly decreased by a change in drug
dose from 1000 to 2000, a further dose increment (up to 3000 mg/
d) was not associated with a worsening of tolerability. This is
different from what has been observed with other AEDs, which
show a clear worsening of tolerability at higher doses [53,55]. The
characteristic LEV tolerability proﬁle was even more evident when
the dose–effect relationship was analyzed for speciﬁc AEs. Only
somnolence seemed to be inﬂuenced by drug dose. Strikingly,
dizziness and irritability have a similar frequency at all drug doses.
Even though the reasons for these atypical ﬁndings are not
clear, the lack of a dose–effect relationship for several AEs can
explain the clinical proﬁle of LEV, which is considered a drug with
a very good tolerability [1,3] and which can be titrated very fast
without severe consequences [40].
Some limitations of this meta-analysis need to be acknowl-
edged. Firstly, RCTs have some limitations that tend to overstate
the effect of a new treatment: the restrictive inclusion and
exclusion criteria may lead to the enrollment of a sample not-
representative of the target patient population. In addition, the
trial relatively short observation period may underestimate long-
term toxicity. Secondly, there may be demographic and clinical
heterogeneity since adults and children with different disorders
could receive many different concomitant therapies. Thirdly, our
analysis focused on the NNH of LEV; however, it is important to
take into account that clinical decisions need to weigh both harm
and beneﬁts, which were not assessed in our study. Fourthly,grouping of synonyms under one single term carries the risk of
double-counting of patients, but this approach was necessary in
our analysis due to the variety of terms used for AE description
in RCTs. Collective efforts should be made to develop a single
standardized terminology for RCTs on AEDs. Finally, our study is
limited by the fact that we did not check the database for clinical
studies and by a potential bias related to studies with high AEs
which have beennot published.
Due to these limitations, the analysis of AEs proﬁle of LEV
requires further investigations and validation.
5. Conclusions
In conclusion, our results show a general good tolerability
proﬁle of LEV, which is characterized mainly by a sedative effect,
reﬂected by somnolence and asthenia/fatigue, minimal neuropsy-
chiatric impairment (nervousness/irritability), along with mild
vestibulocerebellar manifestations, represented by dizziness, and a
weak increase in upper respiratory tract infections.
Of interest, all these 5 AEs did not seem to show a clear dose–
response relationship. Further longitudinal well-conducted inves-
tigations will provide additional data on potential toxic and/or
idiosyncratic effects and help in fully characterize the tolerability
proﬁle of this drug.
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